Atibuclimab Biosimilar – Research Grade
ichorbio’s atibuclimab biosimilar is for Research Use Only (RUO) and not for therapeutic use.
ichorbio’s RUO atibuclimab biosimilar is available in the following sizes:
0.1mg, 5mg, 10mg, 20mg, 50mg
ichorbio regularly manufactures bulk multi-gram amounts of this biosimilar – please contact us for pricing.
Detects human CD14. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody atibuclimab.
This recombinant protein was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
RUO atibuclimab is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis. It acts as a pattern recognition receptor for bacterial cell wall components in gram-positive and negative bacteria. CD14 antibody action stimulates a pro-inflammatory cytokine cascade often associated with inflammation in sepsis. Atibuclimab neutralization of this antibody results in the inhibition of TNF-a, IL-6 and IL-10, dampening systemic inflammatory responses. Atibuclimab also delays the release of sTNFR(1) and IL-1ra.
1.0 – 5.0 mg/ml
Sterile, preservative-free, solution in PBS. BSA and Azide free.
>95% by SDS-PAGE and HPLC
≤ 1.0 EU/mg as determined by the LAL method
Atibuclimab Biosimilar – Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.
Each investigator should determine their own optimal working dilution for specific applications.
ichorbio’s atibuclimab biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.